Business · 09/06/2020Updated: 10/17/2026 · 1 min read
FDA Releases Guidance for Institutional Review Boards Reviewing Individual Patient Expanded Access Requests for COVID-19 Treatments
Summary
The FDA has issued a final guidance to help Institutional Review Boards (IRBs) review individual patient expanded access requests for investigational COVID-19 treatments, allowing patients to access these treatments during the public health emergency.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →